research Targeted Delivery of Zinc Pyrithione to Skin Epithelia
Zinc pyrithione needs targeted delivery to the scalp for effective dandruff treatment.
Search
for
Sort by
Research
180-210 / 1000+ resultsresearch Alopecia areata: Part 2: treatment.
Alopecia areata can be managed with various treatments, and severe cases should be referred to dermatologists.
research Management of Skin Toxicities in Cancer Treatment: An Australian/New Zealand Perspective
Preventing and managing skin issues from cancer treatment is crucial, especially in high UV areas like Australia and New Zealand.
research Progress in Lipid and Inorganic Nanocarriers for Enhanced Skin Drug Delivery
Nanocarriers can improve skin drug delivery but face challenges in clinical use.
research Nutritional Disorders of the Hair and Their Management
research Clinical recognition and management of alopecia in women of color,
The document concludes that it's important to recognize and treat hair loss in women of color, considering their unique hair characteristics and psychological impact.
research Trace element zinc and skin disorders
Zinc is important for skin health, and supplements can help treat various skin and hair disorders, but more research is needed for conditions like psoriasis and vitiligo.
research Dupilumab in the treatment of severe atopic dermatitis refractory to systemic immunosuppression: case report
Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.
research Advance and Challenges in the Treatment of Skin Diseases with the Transdermal Drug Delivery System
New skin disease treatments using TDDS are improving but face challenges like side effects and high costs.
research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
research Efficacy and safety of the Exfoliate-Dissolve-Repair skin care approach in the treatment of keratosis pilaris: a randomized controlled clinical trial study protocol
The Exfoliate-Dissolve-Repair skincare approach may effectively treat keratosis pilaris and reduce the need for corticosteroids.
research Caffeine as an Active Ingredient in Cosmetic Preparations Against Hair Loss: A Systematic Review of Available Clinical Evidence
Caffeine may help with hair loss, but more research is needed.
research Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities
Alopecia Areata causes hair loss and needs treatments that address both physical and emotional health.
research Ernährungsstörungen des Haares und deren Management
research Hair Loss, Diagnosis, and Treatment Planning
research Bioactive Compound-Loaded Nanocarriers for Hair Growth Promotion: Current Status and Future Perspectives
Nanocarriers with plant extracts show promise for safe and effective hair growth treatment.
research Tratamiento de la alopecia areata, un recorrido desde las opciones terapéuticas clásicas hasta los nuevos fármacos aparecidos en los últimos años
Alopecia areata is hard to treat, but new targeted therapies show promise.
research Oral Presentations
Understanding hair health and disorders is important for effective treatment.
research Nanotechnology-based techniques for hair follicle regeneration
Nanotechnology could improve hair regrowth but faces challenges like complexity and safety concerns.
research The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds
Certain natural and synthetic compounds may help treat inflammatory skin diseases by targeting a specific signaling pathway.
research Seborrheic Dermatitis Revisited: Pathophysiology, Diagnosis, and Emerging Therapies—A Narrative Review
New treatments for seborrheic dermatitis show promise for difficult cases.
research Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
Early intervention and tailored management can reduce skin side effects from cancer treatments.
research Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double‐blind placebo‐controlled trial
The new clobetasol propionate foam is effective and safe for treating alopecia areata.
research Clobetasol Propionate, 0.05%, vs Hydrocortisone, 1%, for Alopecia Areata in Children
Clobetasol propionate, 0.05%, is more effective and safe for treating childhood alopecia areata than hydrocortisone, 1%.
research Chromatographic method for clobetasol propionate determination in hair follicles and in different skin layers
A new method accurately measures clobetasol propionate in hair and skin.
research Topical Metformin Compared with Clobetasol Propionate for Alopecia Areata: Clinical Outcomes from a Comparative Study
Clobetasol is more effective than metformin for treating localized alopecia areata.
research COMPARATIVE EFFICACY OF TOPICAL CLOBETASOL PROPIONATE 0.05% OINTMENT AND TOPICAL TACROLIMUS 0.1% OINTMENT IN THE TREATMENT OF ALOPECIA AREATA
Clobetasol propionate 0.05% ointment is more effective than tacrolimus 0.1% ointment for treating alopecia areata.
research Compatibility of 17-a-estradiol, Caffeine, Clobetasol Propionate, Finasteride Melatonin, Metronidazole, Spironolactone, Tretinoin, and Triamcinolone in Trichosol, a Natural Vehicle for Hair Solutions.
TrichoSol™ effectively stabilizes various hair treatment ingredients for different durations.
research Compatibility of Caffeine Clobetasol Propionate Dutasteride Nicotinamide and Progesterone in TrichoFoam™, a Natural Vehicle for Hair Foams.
TrichoFoam™ is a stable option for personalized hair loss treatment with most ingredients remaining effective for 90-180 days.
research Comparative Efficacy of Topical Tacrolimus 0.1% and Clobetasol Propionate 0.05% in the Treatment of Alopecia Areata (AA)
Clobetasol propionate 0.05% is more effective for hair re-growth in alopecia areata than tacrolimus 0.1%.